Heron Therapeutics Inc HRTX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if HRTX is a good fit for your portfolio.
News
-
Heron Therapeutics to Host Investor Day on May 15, 2024 in New York City
-
Heron Therapeutics Announces Presentation at the 23rd Annual Needham Virtual Healthcare Conference
-
Heron Therapeutics Announces Fourth Quarter and Full-Year 2023 Financial Results and Highlights Recent Corporate Updates
-
Heron Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results On Tuesday, March 12, 2024
-
Heron Therapeutics Shares Rise 15% After FDA Approves Expanded Use of Zynrelef
-
Heron Therapeutics Announces FDA Approval of ZYNRELEF® Indication Expansion to Include Additional Orthopedic and Soft Tissue Procedures
Trading Information
- Previous Close Price
- $2.77
- Day Range
- $2.70–2.96
- 52-Week Range
- $0.50–3.22
- Bid/Ask
- $2.65 / $2.84
- Market Cap
- $407.39 Mil
- Volume/Avg
- 892 / 2.3 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 2.95
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Heron Therapeutics Inc is a commercial-stage biotechnology company. It is focused on improving the lives of patients by developing treatments that address some of the unmet patient needs. The company's product portfolio consists of APONVIE, SUSTOL, ZYNRELEF, and CINVANTI.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 126
- Website
- https://www.herontx.com
Comparables
Valuation
|
Metric
|
HRTX
|
AXSM
|
PNT
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | 11.36 |
Price/Book Value | — | 16.29 | 3.12 |
Price/Sales | 2.95 | 11.03 | 5.50 |
Price/Cash Flow | — | — | 13.90 |
Price/Earnings
HRTX
AXSM
PNT
Financial Strength
|
Metric
|
HRTX
|
AXSM
|
PNT
|
|---|---|---|---|
Quick Ratio | 1.76 | 3.46 | 9.01 |
Current Ratio | 2.37 | 3.63 | 9.14 |
Interest Coverage | −28.45 | −35.93 | — |
Quick Ratio
HRTX
AXSM
PNT
Profitability
|
Metric
|
HRTX
|
AXSM
|
PNT
|
|---|---|---|---|
Return on Assets (Normalized) | −34.26% | −29.97% | 20.67% |
Return on Equity (Normalized) | — | −78.66% | 23.56% |
Return on Invested Capital (Normalized) | −52.36% | −41.49% | 23.38% |
Return on Assets
HRTX
AXSM
PNT
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Zlfxcnqtz | Zgmq | $550.4 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Bhkqvskjz | Nkhlmfv | $101.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Rqgqlyy | Wdfpqhb | $98.1 Bil | |
MRNA
| Moderna Inc | Hxpgvnvry | Lyzm | $39.1 Bil | |
ARGX
| argenx SE ADR | Hphfxyxx | Yxh | $21.7 Bil | |
BNTX
| BioNTech SE ADR | Bbfqjgvt | Rwm | $20.8 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Rmqzpjhf | Mwmdhh | $18.4 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Lpwxxsss | Tswbvrn | $17.1 Bil | |
RPRX
| Royalty Pharma PLC Class A | Nylzxjsdg | Fqhxp | $12.5 Bil | |
INCY
| Incyte Corp | Gpdpdysq | Pvbrhj | $11.9 Bil |